Lexeo Therapeutics (LXEO) News Today $4.61 -0.12 (-2.54%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.66 +0.04 (+0.98%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXEO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from BrokeragesAugust 1 at 9:16 AM | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Coverage Initiated by Analysts at OppenheimerAugust 1 at 7:53 AM | marketbeat.comOppenheimer Initiates Coverage of Lexeo Therapeutics (LXEO) with Outperform RecommendationAugust 1 at 5:09 AM | msn.comStifel Maintains Buy Rating on Lexeo Therapeutics (LXEO)July 29, 2025 | msn.comLexeo Therapeutics Holds 2025 Annual Stockholders MeetingJuly 25, 2025 | theglobeandmail.comLexeo Therapeutics (NASDAQ:LXEO) Shares Up 3.6% - Still a Buy?July 10, 2025 | marketbeat.comLexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - MorningstarJuly 8, 2025 | morningstar.comMLexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia Treatment - NasdaqJuly 8, 2025 | nasdaq.comWhy Lexeo Is Rising In Pre-market? - NasdaqJuly 8, 2025 | nasdaq.comLexeo Therapeutics stock rises after FDA breakthrough designationJuly 8, 2025 | au.investing.comLexeo Therapeutics Shares Climb Following FDA Breakthrough Therapy DesignationJuly 8, 2025 | msn.comLexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich AtaxiaJuly 7, 2025 | globenewswire.comLexeo Therapeutics stockholders elect directors and ratify auditor at annual meeting - Investing.comJuly 2, 2025 | investing.comLexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA TherapeuticsJune 24, 2025 | globenewswire.comLexeo Therapeutics files to sell 41.63M shares of common stock for holdersJune 13, 2025 | msn.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Acquired by Millennium Management LLCJune 6, 2025 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $10.00 at JPMorgan Chase & Co.May 31, 2025 | marketbeat.comLeerink Partnrs Issues Positive Forecast for LXEO EarningsMay 31, 2025 | marketbeat.comLexeo Therapeutics Announces $80 Mln Private Placement Of SharesMay 29, 2025 | nasdaq.comLexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular DiseasesMay 27, 2025 | globenewswire.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Buy" by BrokeragesMay 24, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Trims Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)May 23, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Holdings Lifted by Point72 Asset Management L.P.May 22, 2025 | marketbeat.comVestal Point Capital LP Raises Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)May 21, 2025 | marketbeat.comQ1 Earnings Forecast for LXEO Issued By HC WainwrightMay 21, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Holdings Lifted by Janus Henderson Group PLCMay 17, 2025 | marketbeat.comLexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Superior Safety Profile Drive Buy RatingMay 16, 2025 | tipranks.comChardan Capital Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock PriceMay 15, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Sold by Omega Fund Management LLCMay 15, 2025 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Misses Expectations By $0.19 EPSMay 14, 2025 | marketbeat.comLexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational HighlightsMay 12, 2025 | globenewswire.comDAFNA Capital Management LLC Purchases 142,500 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)May 10, 2025 | marketbeat.comLexeo: Alignment Gained With FDA Brings Further LX2006 Program AdvancementMay 5, 2025 | seekingalpha.comLexeo Therapeutics (LXEO) Projected to Post Earnings on ThursdayMay 3, 2025 | marketbeat.comLexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual MeetingMay 1, 2025 | globenewswire.comAdage Capital Partners GP L.L.C. Sells 388,121 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)April 29, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from BrokeragesApril 28, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Sold by D1 Capital Partners L.P.April 26, 2025 | marketbeat.comAltium Capital Management LLC Takes $2.67 Million Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)April 20, 2025 | marketbeat.comWhat is Chardan Capital's Estimate for LXEO FY2025 Earnings?April 13, 2025 | marketbeat.comChardan Capital Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $22.00April 10, 2025 | marketbeat.comLexeo Therapeutics' (LXEO) Buy Rating Reiterated at HC WainwrightApril 10, 2025 | marketbeat.comADAR1 Capital Management LLC Grows Stock Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)April 9, 2025 | marketbeat.comLexeo Therapeutics announces ‘positive’ Interim Phase 1/2 data for LX2006April 8, 2025 | markets.businessinsider.comLexeo Therapeutics price target lowered to $22 from $25 at ChardanApril 8, 2025 | markets.businessinsider.comPromising Developments in Lexeo Therapeutics’ Gene Therapy Trials Support Buy RatingApril 8, 2025 | tipranks.comGene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In TrialsApril 7, 2025 | benzinga.comLexeo Therapeutics Reports Positive Interim Trial ResultsApril 7, 2025 | tipranks.comLexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational StudyApril 7, 2025 | globenewswire.comWhat is Chardan Capital's Forecast for LXEO FY2025 Earnings?March 29, 2025 | marketbeat.com Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address LXEO Media Mentions By Week LXEO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXEO News Sentiment▼0.540.62▲Average Medical News Sentiment LXEO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXEO Articles This Week▼52▲LXEO Articles Average Week Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kura Oncology News Today Oruka Therapeutics News Today Arvinas News Today Rapport Therapeutics News Today aTyr Pharma News Today Opthea News Today Precigen News Today Solid Biosciences News Today Terns Pharmaceuticals News Today Tourmaline Bio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXEO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.